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Despite the small sample size that often complicates research into diseases that affect children,
recent genome sequencing efforts have made astounding progress in discovering the underlying
genetic causes of pediatric diseases, many of which were previously unpredicted. This Select high-
lights recent genetic findings that provide clear insights into disease mechanisms and therapeutic
targets that will open new vistas of treatment development for diseases that affect young children
and adolescents.Structure of a nucleosome showing DNA
wrapped around histone proteins. In pediatric
glioblastoma, the tail of histone H3.3 that
protrudes from the nucleosome is frequently
mutated, disrupting gene expression regulation
across the genome. Image courtesy of Jeremy
Schwartzentruber, produced using Jmol based
on crystal structure 1AOI from the Protein
Data Bank (http://www.pdb.org).Pediatric Glioblastomas Driven by Epigenetic
Changes
Pediatric cases of the aggressive brain cancers glioblastoma multiforme (GBM)
and diffuse intrinsic pontine glioma (DIPG) are difficult to treat and are associ-
ated with high mortality, similar to the adult disease. Current treatment options
are limited, and survival rates are low for patients with tumors that are difficult to
resect. As few as 10% of children with DIPG tumors, which are found entwined
around nerves within the brain stem, survive. It has been clear that the pediatric
formof thediseasediffersmolecularly from the adult version. Two recent studies
now provide a clear link between epigenetic remodeling and childhood glioma
occurrence, based on key differences in the genomic mutations of high-grade
GBM and DIPG pediatric tumors as compared with low-grade tumors, adult
gliomas, or healthy matched tissue. Collectively, Wu et al. (2012) and Schwart-
zentruber et al. (2012) identify three mutually exclusive mutations in the genes
encoding histone H3.3 (Lys27Met andGly34Arg inH3F3A) and the homologous
histone H3.1 (Lys27Met in HIST1H3B). Lysine 27 is a well-known site of histone
posttranslational modification that modulates transcription, and glycine 34 is
nearby to the well-studied modification site lysine 36. Schwartzentruber et al.
(2012) also found mutations in the genes ATRX and DAXX that encode com-
ponents of the chromatin remodelingmachinery. These results identify systemic
changes to chromatin structure and the resulting gene expression patterns as
a driver for these aggressive pediatric tumors. Furthermore, they provide
amuch-needednewpathway that canbe targeted for therapeutic development.
Schwartzentruber, J., et al. (2012). Nature 482, 226–231.Wu, G., et al. (2012). Nat. Genet. Published online January 29, 2012. 10.1038/ng.1102.Targeting the kinase SYK1 may be a new
strategy for treating retinoblastoma,
characterized by aggressive tumors in
the eyes of children. Image by Dimitris
Stephanidesandcourtesyof iStockphoto.Seeing a Target in Retinoblastoma
Like gliomas, retinoblastoma is an aggressive childhood cancer that is characterized by
malignancies in the eyes of very young children. Although generally localized only to the
eyes in the early stages and treatable with radiation, chemotherapy, and ablation, in
extreme cases, surgery is required to remove the eye. In addition to being the most
common genetic lesion underlying the malignancies of the eye, biallelic inactivation of
theRB1genepredisposeschildren todevelopingothercancers throughout their lifetime.
To better understand the etiology of retinoblastoma beyond mutation of RB1, Zhang
et al. (2012) applied whole-genome sequencing techniques to four retinoblastoma
tumors and paired germline tissues. Theywere surprised to find no other obviousmuta-
tions in characterized tumor suppressors or oncogenes beyond the previously identified
MYCN, which is known tobeamplified in retinoblastoma, including tumors that retainRb
activity. This led them to investigate the epigenetic landscape of these tumors with ChIP
sequencing, DNAmethylation, and gene expression analysis. Their studies found induc-
tion in theexpressionof theoncogenic kinaseSYK. KnockdownofSYKexpressionusing
short-hairpinRNAorblockingkinaseactivitywithasmall-molecule inhibitor led to increasedapoptosis in retinoblastomacell lines,
suggesting that therapeutic targeting of SYK could be a beneficial addition to the current treatment protocol for retinoblastoma.
Zhang, J., et al. (2012). Nature 481, 329–334.Cell 148, March 16, 2012 ª2012 Elsevier Inc. 1073
Mutation of Ile500 (red) affects proper
ubiquitination of SMAD4 lysines (blue,
orange). Image courtesy of Valerie
Cormier-Daire.The SMADness of Myhre Syndrome
Myhre syndrome is a rare, sporadic developmental disorder that presents with a
pleiotropic phenotype including short stature and musculoskeletal defects, as well
as intellectual disability, cardiac defects, and deafness. Beginning with samples
from only two affected individuals, whole-exome sequencing efforts by Le Goff
et al. (2012) identified a conserved set of mutations in the tumor suppressor
SMAD4 that were subsequently found in nine additional individuals with the disease.
These mutations all lead to substitution of Ile500 in the MH2 domain of SMAD4 that is
involved in transcriptional regulation. Unlike previously characterized loss-of-function
mutations in various tumors, the Ile500 mutations appear to stabilize the protein by
reducing ubiquitin-mediated degradation without adversely affecting the heterodime-
rization of SMAD4 with other members of the SMAD family. Under normal conditions,
this heterodimerization allows the SMAD proteins to regulate transcription down-
stream of TGF-b and BMP signals, but preliminary analyses of known transcriptional
targets downstream of SMAD/TGF-b in cells from Myhre patients indicate aberrant
regulation by mutant SMAD4. Transcription of a handful of genes downstream of
the SMAD-regulated TGF-b or BMP was either increased or decreased in fibroblastsfrom an individual with Myhre syndrome. The development of treatments for the symptoms of Myhre syndrome will require
significantly more biochemical characterization of the signal pathway disruptions and transcriptional networks that are
affected, but this study has transformed a limited number of samples into strong evidence demonstrating a role for
SMAD4 in the disease etiology of Myhre syndrome.
Le Goff, C., et al. (2012). Nat. Genet. 44, 85–88.The PRRT2 gene encodes a protein of unknown
function. In primary neurons transfected with
PRRT2, neuronal processes are stained for
PRRT2 (mutated in PKD/IC, in red) and MAP2
(in green). Image courtesy of Louis John Ptacek.A Synaptic Connection in Paroxysmal
Kinesigenic Dyskinesia
Paroxysmal kinesigenic dyskinesia, an unusual autosomal-dominant inherited
neuronal disorder that causes infantile convulsions in very young patients and
uncontrolled movement disorder later in childhood and adolescence, is another
example of determining the etiology of a rare disorder through whole-genome
sequencing. The disease is unusual as the dyskinesia initially worsens but
then often improves as a patient ages and recedes later in adulthood. The genes
harboring mutations underlying PKD have eluded researchers for more than
a decade, but recent sequencing efforts by Lee et al. (2012) and others identi-
fied truncating mutations in PRRT2 as a primary cause of this disorder. The
product of PRRT2 is a proline-rich transmembrane protein primarily expressed
in the central nervous system and whose function is unknown. PRRT2 was
suggested to physically interact with SNAP25, a t-SNARE protein involved in
vesicle fusion, raising the possibility that loss of functional PRRT2 function
leads to synaptic dysfunction. In addition to identifying the genetic lesions in
PRRT2, experiments by Lee et al. (2012) validated the association with
SNAP25 and demonstrate that the disease-associated mutations reduce or
eliminate expression of PRRT2, abrogating this interaction. Although many
studies remain to be completed before the disease mechanism is fully under-
stood, this recent work has helped to remove the first major obstacle for treat-
ment development and has opened the door for more rapid progress toward
a therapy.
Lee, H.-Y., et al. (2012). Cell Rep. 1, 2–12.
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